Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, these discussions reflect strong interest and some agreement with the promising trial results, exemplified by mentions of the ORR percentage, durable responses, and the potential broad efficacy regardless of HER3 expression levels, with tone emphasizing enthusiasm and cautious optimism, which indicates recognition of the treatment's significance in advanced lung cancer therapy.
Most discussions support the promising results and potential of the HER3-DXd treatment, reflecting a positive consensus.
The discussions show high engagement with detailed data points, indicating genuine interest in the trial outcomes.
Comments include references to specific metrics like ORR, DoR, and PFS, and some interpret implications, showing moderate engagement.
The discussions highlight potential clinical implications, especially regarding efficacy in complex cases like brain metastases, indicating a moderate impact perception.
Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (30%), PFS 5.5 months. Similar to what seen in breast cancer, HER3 IHC expression was not found associated with the activity of the ADC. https://t.co/iILIBD6att https://t.co/RcYB8S1VIi
EGFR変異陽性非小細胞肺癌のパトリツマブデルクステカン（HER3-DXd）第2相HERTHENA-Lung01試験。EGFR-TKIとプラチナ化学療法の後で、ORR約30%で（脳転移病変の別評価も同じくらい）、HER3の発現度合いやEGFR耐性変異の種類にあまり関係なく有効性を発揮したとのこと。／JCO https://t.co/AaKwVnI7kv
HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were treated w/ Patritumab deruxtecan (HER3-DXd) ➡️ORR 29.8% ➡️Md DoR 6.4 mo ➡️Md PFS 5.5 mo ➡️Md OS 11.9 mo #LCSM @OncoAlert @BTFCancerNews https://t.co/Da3Gpz73SB
#HER3 expression level is not a predictive biomarker for the efficacy of HER3-Dxd. The #HERTHENA-Lung01 trial and the BRE 354 trial showed similar results. Ref: https://t.co/vyyfnqafcl https://t.co/G0sGvSUWuO https://t.co/cRMTAmyEfS
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy https://t.co/rK7twdjeAK
What’s popular this week in #JCO? HERTHENA-Lung01 a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated #NSCLC After Epidermal Growth Factor Receptor TKI Therapy & Platinum-Based Chemo ➡️ https://t.co/eGLq6gMFMi #lcsm https://t.co/KNtNiY8jSq
This video discusses the phase II trial of HER3-DXd, an antibody-drug conjugate, in EGFR-mutated NSCLC patients post therapies, showing promising response rates, durable responses, and efficacy even in patients with…
LUNG: in a phase 2 study, an ERBB3 ADC (patritumab deruxtecan) delivered ORR 30% DoR 6.4 months in patients with EGFR mutant tumours who had failed both tyrosine kinase inhibitor and platinum-based therapy. https://t.co/rYtEbwdEk9
RT @raffcolo: https://t.co/VQj2GXXxyL
https://t.co/VQj2GXXxyL
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated NonSmall-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy https://t.co/O1Tqy8lpnr #ScientiaVH
Qui i risultati promettenti dell' HERTHENA-Lung01 trial, uno studio di fase II su Patritumab Deruxtecan, nel cancro polmonare non a piccole cellule con mutazione EGFR, dopo terapia con un inibitore TK e chemioterapia a base di platino... https://t.co/8CMNVdmORW
RT @onco_park: #HER3 expression level is not a predictive biomarker for the efficacy of HER3-Dxd. The #HERTHENA-Lung01 trial and the BRE 35…
RT @onco_park: #HER3 expression level is not a predictive biomarker for the efficacy of HER3-Dxd. The #HERTHENA-Lung01 trial and the BRE 35…
Targeted bombing #ADC Confirmed ORR by BICR was 29.8% (95% CI, 23.9 to 36.2); median duration of response, 6.4 months; median progression-free survival, 5.5 months; and median overall survival, 11.9 months. https://t.co/ZS6maA81D9
RT @onco_park: #HER3 expression level is not a predictive biomarker for the efficacy of HER3-Dxd. The #HERTHENA-Lung01 trial and the BRE 35…
RT @onco_park: #HER3 expression level is not a predictive biomarker for the efficacy of HER3-Dxd. The #HERTHENA-Lung01 trial and the BRE 35…
#HER3 expression level is not a predictive biomarker for the efficacy of HER3-Dxd. The #HERTHENA-Lung01 trial and the BRE 354 trial showed similar results. Ref: https://t.co/vyyfnqafcl https://t.co/G0sGvSUWuO https://t.co/cRMTAmyEfS
LUNG: in a phase 2 trial of EGFR-mutant NSCLC with tumour progression following EGFR TKI and platinum chemo, an ERBB3 (HER3)-ADC (patritumab deruxtecan) delivered ORR 30%, median DoR 6.4 months; level of ERBB3 expression was not correlated with response. https://t.co/rYtEbwd6uB
"After tumor progression with EGFR TKI therapy and PBC in patients with EGFR-mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases." https://t.co/LREwSefTdI
RT @JCO_ASCO: What’s popular this week in #JCO? HERTHENA-Lung01 a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth…
RT @JCO_ASCO: What’s popular this week in #JCO? HERTHENA-Lung01 a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth…
What’s popular this week in #JCO? HERTHENA-Lung01 a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated #NSCLC After Epidermal Growth Factor Receptor TKI Therapy & Platinum-Based Chemo ➡️ https://t.co/eGLq6gMFMi #lcsm https://t.co/KNtNiY8jSq
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
RT @DipeshUpretyMD: HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were tr…
HERTHENA-Lung01: Pts with advanced EGFR-mutant NSCLC with ds progression on EGFR TKI and platinum-doublet chemo were treated w/ Patritumab deruxtecan (HER3-DXd) ➡️ORR 29.8% ➡️Md DoR 6.4 mo ➡️Md PFS 5.5 mo ➡️Md OS 11.9 mo #LCSM @OncoAlert @BTFCancerNews https://t.co/Da3Gpz73SB
Un nuovo farmaco, il Patritumab Deruxtecan (HER3-DXd), potrebbe essere efficace laddove un inibitore della TK e una chemioterapia a base di cisplatino hanno già fallito... https://t.co/8CMNVdmORW
RT @BoutAn05: hope for #EGFRmut #LungCa HERTHENA-Lung01 PhII Trial of Patritumab Deruxtecan (HER3-DXd) #NSCLC After EGFR-TKI and Chemo htt…
hope for #EGFRmut #LungCa HERTHENA-Lung01 PhII Trial of Patritumab Deruxtecan (HER3-DXd) #NSCLC After EGFR-TKI and Chemo https://t.co/vgUN3aYAGJ
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy Platinum https://t.co/CsHmtincLH #hvhebron #onco [Text complet]
RT @RManochakian:
RT @RManochakian:
RT @RManochakian:
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @RManochakian:
RT @m0370: EGFR変異陽性非小細胞肺癌のパトリツマブデルクステカン（HER3-DXd）第2相HERTHENA-Lung01試験。EGFR-TKIとプラチナ化学療法の後で、ORR約30%で（脳転移病変の別評価も同じくらい）、HER3の発現度合いやEGFR耐性変異の種類…
RT @RManochakian:
RT @RManochakian:
RT @JCO_ASCO: ‼️ #WCLC23 simultaneous publication in #JCO by Helena Alexandra Yu et al: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated #N…
RT @JCO_ASCO: ‼️ #WCLC23 simultaneous publication in #JCO by Helena Alexandra Yu et al: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated #N…
RT @JCO_ASCO: ‼️ #WCLC23 simultaneous publication in #JCO by Helena Alexandra Yu et al: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated #N…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @Polarbear900R: HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated NSCLC…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated NSCLC After EGFR TKI Therapy and Platinum-Based Chemotherapy | Journal of Clinical Oncology https://t.co/fXqiJ11Ank
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @VivekSubbiah: HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Sma…
RT @VivekSubbiah: HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Sma…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @JCO_ASCO: ‼️ #WCLC23 simultaneous publication in #JCO by Helena Alexandra Yu et al: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated #N…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
‼️ #WCLC23 simultaneous publication in #JCO by Helena Alexandra Yu et al: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated #NSCLC following EGFR TKI therapy and platinum-based chemotherapy: HERTHENA-Lung01 #WCLC23. https://t.co/jyXqm022tQ https://t.co/tAeM1lT5OW
RT @m0370: EGFR変異陽性非小細胞肺癌のパトリツマブデルクステカン（HER3-DXd）第2相HERTHENA-Lung01試験。EGFR-TKIとプラチナ化学療法の後で、ORR約30%で（脳転移病変の別評価も同じくらい）、HER3の発現度合いやEGFR耐性変異の種類…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @m0370: EGFR変異陽性非小細胞肺癌のパトリツマブデルクステカン（HER3-DXd）第2相HERTHENA-Lung01試験。EGFR-TKIとプラチナ化学療法の後で、ORR約30%で（脳転移病変の別評価も同じくらい）、HER3の発現度合いやEGFR耐性変異の種類…
RT @m0370: EGFR変異陽性非小細胞肺癌のパトリツマブデルクステカン（HER3-DXd）第2相HERTHENA-Lung01試験。EGFR-TKIとプラチナ化学療法の後で、ORR約30%で（脳転移病変の別評価も同じくらい）、HER3の発現度合いやEGFR耐性変異の種類…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @m0370: EGFR変異陽性非小細胞肺癌のパトリツマブデルクステカン（HER3-DXd）第2相HERTHENA-Lung01試験。EGFR-TKIとプラチナ化学療法の後で、ORR約30%で（脳転移病変の別評価も同じくらい）、HER3の発現度合いやEGFR耐性変異の種類…
EGFR変異陽性非小細胞肺癌のパトリツマブデルクステカン（HER3-DXd）第2相HERTHENA-Lung01試験。EGFR-TKIとプラチナ化学療法の後で、ORR約30%で（脳転移病変の別評価も同じくらい）、HER3の発現度合いやEGFR耐性変異の種類にあまり関係なく有効性を発揮したとのこと。／JCO https://t.co/AaKwVnI7kv
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @aminfield: HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-…
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy https://t.co/2l6qomADJP
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy | JCO https://t.co/xGZmv3Bopn
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy https://t.co/rK7twdjeAK
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
RT @PTarantinoMD: Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (3…
Out on @JCO_ASCO results from HERTHENA-Lung01, testing HER3-DXd for pretreated EGFR-mut NSCLC. Promising response rate (30%), PFS 5.5 months. Similar to what seen in breast cancer, HER3 IHC expression was not found associated with the activity of the ADC. https://t.co/iILIBD6att https://t.co/RcYB8S1VIi
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
* https://t.co/2SaWEsVNLN
RT @StephenVLiu: Report on HER3-DXd (patritumab deruxtecan, HER3 ADC) in #EGFR NSCLC published @JCO_ASCO after #WCLC23. At 5.6 mg/kg, RR 29…
Source: ascopubs.org/doi/full/10.1200/JCO.23.01476. Related Posts. Next-Gen Stool DNA: The Only Efficient Noninvasive CRC Test. Jolynn Tumolo Gastroenterology ...
doi:10.1200/JCO.23.01476; Mok T, Yu H, Lim SM, Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell ...
doi: 10.1200/JCO.23.01476. Newsletter. Stay up to date on recent advances in the multidisciplinary approach to cancer. Subscribe Now ...
doi:10.1200/JCO.23.01476. Newsletter. Stay up to date on the most recent and practice-changing oncology data. Subscribe Now! Advertisement ...
doi:10.1200/JCO.23.01476; Patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with EGFR-mutated ...
Doi:10.1200/jco.23.01476. Newsletter. Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy ...
doi:10.1200/JCO.23.01476. Newsletter. Stay up to date on the most recent and practice-changing oncology data. Subscribe Now! Advertisement ...
doi:10.1200/JCO.23.01476; Johnson ML, Jänne PA, Goto Y, et al. Intracranial efficacy of HER3-DXd in patients with previously treated advanced ...
doi:10.1200/JCO.23.01476; Schoenfeld AJ, Yu HA. The evolving landscape of resistance to osimertinib. J Thorac Oncol. 2020;15(1):18-21. doi ...
doi:10.1200/JCO.23.01476; HERTHENA-Lung02: a study of patritumab deruxtecan versus platinum-based chemotherapy in metastatic or locally ...
doi:10.1200/JCO.23.01476. Newsletter. Stay up to date on recent advances in the multidisciplinary approach to cancer. Subscribe Now ...
doi:10.1200/jco.23.01476. Newsletter. Stay up to date on recent advances in the multidisciplinary approach to cancer. Subscribe Now ...
doi:10.1200/JCO.23.01476. Newsletter. Stay up to date on the most recent and practice-changing oncology data. Subscribe Now! Advertisement ...
JCO; Published online 10 Sptember 2023. DOI: 10.1200/JCO.23.01476. 4. Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC ...
... 10.1200/JCO.23.01476?role=tab #choosehope #coblh #research #lungcancer #cancer #treatment #clinician. Join ·
doi: 10.1200/JCO.23.01476. 新药. U3-1402（Patritumab Deruxtecan）. 适合人群：EGFR-TKI治疗失败未经过化疗或免疫治疗的晚期肺癌患者. 入组用药：U3 ...
doi: 10.1200/JCO.23.01476. Epub ahead of print. PMID: 37689979. 发布于：江苏省. 平台声明. 评论. 全部. 还没有人评论过，快来抢首评. 写评论.
... 10.1200/JCO.23.01476. Comment. Please enable JavaScript to view the comments powered by Disqus.
doi:10.1200/JCO.23.01476. More from WCLC. Previous. Dr Eric K. Singhi's Top 5 Studies From WCLC 2025: A Thoracic Oncologist's Perspective.
doi:10.1200/JCO.23.01476; Patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with EGFR-mutated ...
org/doi/pdf/10.1200/JCO.23.01476?role=tab #choosehope #coblh #research #lungcancer #cancer #treatment #clinician · May be an image of 1 person ...
PT
レ
DF
BP
VM
JO
CE
KM
AC
RC
B
AI
SA
LA
BW
AH
ÜT
MR
DM
CZ
HK
DB
PB
S
O
L
AF
AT
AB
AM
DH
GB
ES
AM
嫁絶
KP
A
MS
ON
RA
EP
AC
C
MM
じ
GP
TP
Ｙ
羽
T
C
SI
SV
G
よ
TY
JB
PG
GB
I
MT
CJ
TP
MG
N
DS
NF
FB
DM
B
SM
IM
A